{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:48Z","timestamp":1786369428402,"version":"build-2736575974"},"reference-count":59,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T00:00:00Z","timestamp":1179705600000},"content-version":"vor","delay-in-days":1481,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:p> <jats:italic>High blood pressure is the most common chronic medical problem prompting visits to primary health care providers, yet it is estimated that only 34% of the 50 million American adults with hypertension have their blood pressure controlled to a level of &lt;140\/90 mm Hg. Thus, about two thirds of Americans with hypertension are at increased risk for cardiovascular events. The medical, economic, and human costs of untreated and inadequately controlled high blood pressure are enormous. Adequate management of hypertension can be hampered by inadequacies in the diagnosis, treatment, and\/or control of high blood pressure. Health care providers face many obstacles to achieving blood pressure control among their patients, including a limited ability to adequately lower blood pressure with monotherapy and a typical reluctance to increase therapy (either in dose or number of medications) to achieve blood pressure goals. Patients also face important challenges in adhering to multidrug regimens and accepting the need for therapeutic lifestyle changes. Nonetheless, the achievement of blood pressure goals is possible, and, most importantly, lowering blood pressure significantly reduces cardiovascular morbidity and mortality, as proved in clinical trials. The medical and human costs of treating preventable conditions such as stroke, heart failure, and end\u2010stage renal disease can be reduced by antihypertensive treatment. The recurrent and chronic morbidities associated with hypertension are costly to treat. Pharmacotherapy for hypertension therefore offers a substantial potential for cost savings. Pharmacoeconomic analyses regarding antihypertensive drug therapies, their costs, and the relevant reductions in health care expenditures are a useful framework for optimizing current strategies for hypertension management.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1524-6175.2003.02463.x","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T17:31:10Z","timestamp":1179768670000},"page":"3-13","source":"Crossref","is-referenced-by-count":75,"title":["The Economic Impact of Hypertension"],"prefix":"10.1111","volume":"5","author":[{"given":"William J.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,5,21]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Deaths: Preliminary Data for 2001","author":"Arias E","year":"2003"},{"key":"e_1_2_6_3_2","volume-title":"Heart Disease and Stroke Statistics\u20102003 Update","author":"American Heart association","year":"2002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.9.794"},{"key":"e_1_2_6_6_2","first-page":"11","volume-title":"National Conference on High Blood Pressure Education: Report of Proceedings","author":"Stamler J","year":"1973"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)00273-9"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410050036006"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06710-1"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003417"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.5.1021"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430100105012"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340103"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03307-9"},{"key":"e_1_2_6_16_2","volume-title":"National Ambulatory Medical Care Survey: 1995\u201396 Summary. Vital and Health Statistics","author":"Schappert SM"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.15.2281"},{"key":"e_1_2_6_18_2","first-page":"333","article-title":"Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP)","volume":"12","author":"Mehta SS","year":"1999","journal-title":"Am J Hypertens"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.91020.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392701"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010273"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.13.1481"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.3.428"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"United Kingdom Prospective Diabetes Study group","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"e_1_2_6_27_2","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio RO","year":"2000","journal-title":"Diabetes Care"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.1.199"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16225"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7236.705"},{"key":"e_1_2_6_31_2","first-page":"625","article-title":"The 2001 Canadian recommendations for the management of hypertension: part two\u2010therapy","volume":"18","author":"McAlister FA","year":"2002","journal-title":"Can J Cardiol"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2000.03.940"},{"key":"e_1_2_6_33_2","volume-title":"Hospitalization in the United States, 1997","author":"Elixhauser A","year":"2000"},{"key":"e_1_2_6_34_2","volume-title":"Procedures in U.S. Hospitals, 1997","author":"Elixhauser A","year":"2001"},{"key":"e_1_2_6_35_2","first-page":"88","article-title":"Cost\u2010minimization analysis of initial antihypertensive therapy in patients with mild\u2010to\u2010moderate essential diastolic hypertension","volume":"16","author":"Hilleman DE","year":"1994","journal-title":"Clin Ther"},{"key":"e_1_2_6_36_2","first-page":"389","article-title":"Impact of poorly controlled hypertension on healthcare resource utilization and cost","volume":"7","author":"Paramore LC","year":"2001","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.6.880"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","first-page":"I16","DOI":"10.1007\/BF03404494","article-title":"Adherence to pharmacologic management of hypertension","volume":"89","author":"Feldman R","year":"1998","journal-title":"Can J Public Health"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-996-0018-7"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","unstructured":"BobalE O'ConnerDL KeefeJ.Trends in the treatment of hypertension within managed care organizations: a national survey of HMO pharmacy directors. Academy Managed Care Pharmacy (online publication). May\/June 1998;3(3). Available at:http:www.amcp.orgjmcpvol3num3hyper.html. Accessed February 19 2002.","DOI":"10.18553\/jmcp.1997.3.3.317"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.1996.11946111"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110103251505"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00161-2"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03791.x"},{"issue":"1","key":"e_1_2_6_45_2","first-page":"S90","article-title":"Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy","volume":"16","author":"Parving HH","year":"1998","journal-title":"J Hypertens Suppl"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-9-199911020-00005"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199201040-00003"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92589-T"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6488.97"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-996-0036-5"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7160.720"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.00469.x"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000855"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6824.405"},{"key":"e_1_2_6_55_2","first-page":"1261","article-title":"Report by the Management Committee","volume":"1","author":"The Australian therapeutic trial in mild hypertension","year":"1980","journal-title":"Lancet"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05381-6"},{"key":"e_1_2_6_57_2","first-page":"3255","article-title":"Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group","volume":"266","author":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91783-0"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6555.1145"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816120-00016"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-6175.2003.02463.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1524-6175.2003.02463.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:00:26Z","timestamp":1694397626000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-6175.2003.02463.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1111\/j.1524-6175.2003.02463.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-6175.2003.02463.x","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}